Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era
August 24th 2020In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.
Read More
Pegram Unpacks Pivotal Data in Breast Cancer
August 17th 2020In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.
Read More
Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma
August 13th 2020In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
Read More
Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer
August 10th 2020In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.
Read More
Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
August 6th 2020In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.
Read More
FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL
August 3rd 2020In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.
Read More
Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
July 27th 2020In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.
Read More
Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
July 23rd 2020In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.
Read More
FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers
July 20th 2020In our exclusive interview, Alexander Drilon, MD provided background on use of targeted therapy in advanced non–small cell lung cancer, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.
Read More
Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos
July 16th 2020In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.
Read More
First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma
July 13th 2020In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.
Read More
Marvels in Medicine: Dr. Jordan on Undertaking an Unforeseen Career in Breast Cancer
July 9th 2020In our exclusive interview, Dr. Jordan explains how he became “The Father of Tamoxifen,” details his work with British Special Forces during the Cold War, and discusses how his career in science started by setting his parents’ house on fire.
Read More
FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC
July 6th 2020Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.
Read More
Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC
June 29th 2020Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.
Read More
Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer
June 22nd 2020In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.
Read More
FDA Approves Selinexor for Relapsed/Refractory DLBCL
June 22nd 2020The FDA has approved selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
Read More
Integrating Nutrition Into the Continuum of Cancer Care
June 18th 2020In our exclusive interview, Dr. Hegazi, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.
Read More
Marvels in Medicine: Dr. Gradishar on the Personal Pursuit of Precision Medicine in Breast Cancer
June 11th 2020In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.
Read More
FDA Approves Pfizer’s Pegfilgrastim Biosimilar
June 11th 2020The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Read More
Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
June 9th 2020Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.
Read More
Research Reflections: Hamid Homes in on Key Efforts Made in Melanoma
June 8th 2020Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.
Read More